BGM Group Ltd. (BGM)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov... | PHASE3 | Recruiting | 12,800 |
| NCT06592794 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acu... | PHASE3 | Active Not Recruiting | 37,864 |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell... | PHASE3 | Active Not Recruiting | 600 |
| NCT05035212 | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | PHASE3 | Active Not Recruiting | 38,861 |
| NCT05575492 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Year... | PHASE2 | Active Not Recruiting | 873 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.